Literature DB >> 27456385

Development of Celiac Disease Therapeutics: Report of the Third Gastroenterology Regulatory Endpoints and Advancement of Therapeutics Workshop.

Daniel Leffler1, Sonia S Kupfer2, Benjamin Lebwohl3, Kevin Bugin4, Donna Griebel4, Julia Tait Lathrop4, Jessica J Lee4, Andrew E Mulberg4, Elektra Papadopoulos4, Juli Tomaino4, Sheila E Crowe5.   

Abstract

Mesh：

Year:  2016        PMID： 27456385     DOI： 10.1053/j.gastro.2016.07.025

Source DB:  PubMed          Journal:  Gastroenterology        ISSN： 0016-5085            Impact factor:   22.682


× No keyword cloud information.
  9 in total

Review 1.  (Outcome) Measure for (Intervention) Measures: A Guide to Choosing the Appropriate Noninvasive Clinical Outcome Measure for Intervention Studies in Celiac Disease.

Authors:  Prashant Singh; Jocelyn A Silvester; Daniel Leffler
Journal:  Gastroenterol Clin North Am       Date:  2018-12-13       Impact factor: 3.806

2.  Latiglutenase Improves Symptoms in Seropositive Celiac Disease Patients While on a Gluten-Free Diet.

Authors:  Jack A Syage; Joseph A Murray; Peter H R Green; Chaitan Khosla
Journal:  Dig Dis Sci       Date:  2017-07-28       Impact factor: 3.199

Review 3.  Non Celiac Gluten Sensitivity.

Authors:  Maria Teresa Bardella; Luca Elli; Francesca Ferretti
Journal:  Curr Gastroenterol Rep       Date:  2016-12

4.  Eliminating Dietary Gluten: Don't Be a "Glutton for Punishment".

Authors:  Prashant Singh; Melinda Dennis
Journal:  Dig Dis Sci       Date:  2018-06       Impact factor: 3.199

Review 5.  Tests for Serum Transglutaminase and Endomysial Antibodies Do Not Detect Most Patients With Celiac Disease and Persistent Villous Atrophy on Gluten-free Diets: a Meta-analysis.

Authors:  Jocelyn A Silvester; Satya Kurada; Andrea Szwajcer; Ciarán P Kelly; Daniel A Leffler; Donald R Duerksen
Journal:  Gastroenterology       Date:  2017-05-22       Impact factor: 22.682

6.  Latiglutenase Treatment for Celiac Disease: Symptom and Quality of Life Improvement for Seropositive Patients on a Gluten-Free Diet.

Authors:  Jack A Syage; Peter H R Green; Chaitan Khosla; Daniel C Adelman; Jennifer A Sealey-Voyksner; Joseph A Murray
Journal:  GastroHep       Date:  2019-10-08

7.  A B-Cell Gene Signature Correlates With the Extent of Gluten-Induced Intestinal Injury in Celiac Disease.

Authors:  Mitchell E Garber; Alok Saldanha; Joel S Parker; Wendell D Jones; Katri Kaukinen; Kaija Laurila; Marja-Leena Lähdeaho; Purvesh Khatri; Chaitan Khosla; Daniel C Adelman; Markku Mäki
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2017-01-28

8.  Outcome measures in coeliac disease trials: the Tampere recommendations.

Authors:  Jonas F Ludvigsson; Carolina Ciacci; Peter Hr Green; Katri Kaukinen; Ilma R Korponay-Szabo; Kalle Kurppa; Joseph A Murray; Knut Erik Aslaksen Lundin; Markku J Maki; Alina Popp; Norelle R Reilly; Alfonso Rodriguez-Herrera; David S Sanders; Detlef Schuppan; Sarah Sleet; Juha Taavela; Kristin Voorhees; Marjorie M Walker; Daniel A Leffler
Journal:  Gut       Date:  2018-02-13       Impact factor: 23.059

9.  Society for the Study of Celiac Disease position statement on gaps and opportunities in coeliac disease.

Authors:  M Ines Pinto-Sanchez; Jocelyn A Silvester; Benjamin Lebwohl; Daniel A Leffler; Robert P Anderson; Amelie Therrien; Ciaran P Kelly; Elena F Verdu
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-09-15       Impact factor: 46.802
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.